The top after-market NASDAQ gainers Thursday were TFS Financial Corporation, Brightcove Inc, Pactera Technology International Ltd, United Bankshares Inc and Warren Resources Inc.

The top after-market NASDAQ losers Thursday were Alexza Pharmaceuticals Inc, Raptor Pharmaceutical Corp, Celldex Therapeutics and NuPathe Inc.

Gainers

TFS Financial Corporation (TFSL) shares climbed 5.56 percent to $9.50 in post-market trading. The stock has a 52-week trading range of $8.10-$9.99 and a market capitalization of 2.78 billion.

Brightcove Inc (BCOV) shares gained 3.74 percent to $9.70 in post-market trading. The stock has a 52-week trading range of $8.26-$25.50 and a market capitalization of 260.11 million.

Pactera Technology International Ltd (PACT) shares rose 3.27 percent to $7.26 in post-market trading. The company announced that its Board of Directors had approved a share repurchase program to repurchase up to $30 million worth of outstanding American Depositary Shares (the ADSs) representing the common shares of Pactera from time to time over the next 12 months, depending on market conditions, share price and other factors.

United Bankshares Inc (UBSI) shares advanced 3.13 percent to $24.85 in post-market trading. The stock has a 52-week trading range of $22.54-$30.91 and a market capitalization of 1.21 billion.

Warren Resources Inc (WRES) shares went up by 2.85 percent to $2.89 in post-market trading. The stock has a 52-week low of $2.08, a 52-week high of $4.36 and $201.89 million in market capitalization.

Losers

Alexza Pharmaceuticals Inc (ALXA) shares declined 12.78 percent to $5.05 in post-market trading. The company said that the U.S. Food and Drug Administration approved its schizophrenia and bipolar disorder treatment Adasuve.

Raptor Pharmaceutical Corp (RPTP) shares slumped 12.37 percent to $5.03 in post-market trading. The company said the FDA's decision on its New Drug Application for RP103 (PROCYSBI) for the potential treatment of nephropathic cystinosis would be delayed by three months. The date of decision was originally set for January 30, 2013, but it has been extended by three months to provide more time to the regulatory agency to complete the review.

Celldex Therapeutics Inc (CLDX) shares dropped 4.98 percent to $6.30 in post-market trading. The stock has a 52-week low of $2.53, a 52-week high of $7.20 and $410.90 million in market capitalization.

NuPathe Inc (PATH) shares fell 3.19 percent to $3.34 in post-market trading. The stock has a 52-week low of $1.52, a 52-week high of $5.10 and $50.90 million in market capitalization.

RELATED STORIES